MedTrace Logo

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

NCT03163849 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-09-12

No results posted yet for this study

Summary

Chronic hepatitis C virus infection affects an estimated one hundred and seventy million people around the world with and approximate prevalence 0.2-2 % in the United State of America and European countries.

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Sofosbuvir , daclatasvir

Tablets

DRUG

Placebos

oral tablets

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Sahar Ali, Master Degree · Internal medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-06-01
Completion
2020-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163849 on ClinicalTrials.gov